Anchor International Limited于2026年9月20日，因与同源康医药-B（02410）签订的认购协议（日期为2026年7月21日）所载先决条件未获满足或豁免，协议按修订后最后截止日期失效，故不再持有同源康医药-B任何H股股份。
Anchor International Limited此次减持前持有同源康医药-B好仓6,322.27万股，占比16.63%；减持后持股量为0股，好仓比例降至0.0%。
Anchor International Limited于2026年9月20日，因与同源康医药-B（02410）签订的认购协议（日期为2026年7月21日）所载先决条件未获满足或豁免，协议按修订后最后截止日期失效，故不再持有同源康医药-B任何H股股份。
Anchor International Limited此次减持前持有同源康医药-B好仓6,322.27万股，占比16.63%；减持后持股量为0股，好仓比例降至0.0%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.